Physician profile
Robert L Wilson
NPI 1568413466
$5,173.92
in general payments reported to CMS, 2019-2025
28 companies · $2,133 in 2025
The $2,133 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.79 · 2020: $38.88 · 2021: $234 · 2022: $1,264 · 2023: $524 · 2024: $923 · 2025: $2,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,041 · Travel and Lodging: $1,507 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,041.36 |
| Travel and Lodging | $1,506.52 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $2,527.11 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $748.56 | 2019-2025 | |
| Amgen INC. | $247.33 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $246.07 | 2020-2022 | |
| Edwards Lifesciences Corporation | $204.27 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $159.53 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $125.05 | 2022-2025 | Onpattro |
| Abbott Laboratories | $123.36 | 2021-2024 | Mitraclip, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $89.13 | 2022-2024 | Farxiga |
| Inspire Medical Systems, INC. | $85.64 | 2024 | Inspire |
| Cleerly, INC. | $75.40 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Novo Nordisk INC | $74.70 | 2022-2025 | Wegovy |
| Cvrx, INC. | $65.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.81 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $49.95 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.48 | 2021-2024 | Verquvo |
| Abiomed | $38.36 | 2024-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $36.01 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.14 | 2024 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.64 | 2019-2024 | Lifevest |
| Amarin Pharma, INC. | $24.89 | 2020-2021 | |
| Esperion Therapeutics, INC. | $18.62 | 2021 | |
| Atricure, INC. | $15.36 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $14.37 | 2022 | |
| Medtronic, INC. | $14.20 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.72 | 2024 | |
| Boston Scientific Corporation | $13.14 | 2023 | Watchman Access System |
| Chiesi USA, INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.